bcl-2 antisense therapy chemosensitizes human melanoma in SCID mice
- 1 February 1998
- journal article
- research article
- Published by Springer Nature in Nature Medicine
- Vol. 4 (2) , 232-234
- https://doi.org/10.1038/nm0298-232
Abstract
No abstract availableKeywords
This publication has 10 references indexed in Scilit:
- Translating genomics information into therapeutics: A key role for oligonucleotidesNature Biotechnology, 1997
- BCL-2 antisense therapy in patients with non-Hodgkin lymphomaThe Lancet, 1997
- Bcl-2 expression in malignant melanoma and its prognostic significanceEuropean Journal of Surgical Oncology, 1996
- Antitumor activity of a phosphorothioate antisense oligodeoxynucleotide targeted against C-raf kinaseNature Medicine, 1996
- Apoptosis and chemotherapy resistanceEuropean Journal Of Cancer, 1996
- Does antisense exist?Nature Medicine, 1995
- bcl-2 expression in primary malignancies of the skinArchives of Dermatology, 1995
- CpG motifs in bacterial DNA trigger direct B-cell activationNature, 1995
- bcl-2 Protein Expression in Cutaneous Malignant Melanoma and Benign Melanocytic NeviThe American Journal of Dermatopathology, 1995
- Antisense Oligonucleotides as Therapeutic Agents—Is the Bullet Really Magical?Science, 1993